Retinopathy Of Prematurity - Pipeline Review, H2 2019

Published by Global Markets Direct on 18th November 2019 | Ref: 1464120 | This Product Is In Stock

$2000 | Single User
$4000 | Site License
$6000 | Enterprise License
$2000 | Single User
$4000 | Site License
$6000 | Enterprise License

Introduction

Retinopathy Of Prematurity - Pipeline Review, H2 2019

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Retinopathy Of Prematurity - Pipeline Review, H2 2019, provides an overview of the Retinopathy Of Prematurity (Ophthalmology) pipeline landscape.

Retinopathy of prematurity (ROP) is a disease that affects immature vasculature in the eyes of premature babies. This disorder which usually develops in both eyes is one of the most common causes of visual loss in childhood and can lead to lifelong vision impairment and blindness Risk factors for the development of ROP include prematurity, extremely low-birth-weight, and multiple births.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Retinopathy Of Prematurity - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Retinopathy Of Prematurity (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Retinopathy Of Prematurity (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Retinopathy Of Prematurity and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II and Preclinical stages are 1, 1, 2 and 8 respectively.

Retinopathy Of Prematurity (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Retinopathy Of Prematurity (Ophthalmology).

- The pipeline guide reviews pipeline therapeutics for Retinopathy Of Prematurity (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Retinopathy Of Prematurity (Ophthalmology) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Retinopathy Of Prematurity (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Retinopathy Of Prematurity (Ophthalmology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Retinopathy Of Prematurity (Ophthalmology).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Retinopathy Of Prematurity (Ophthalmology) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Retinopathy Of Prematurity - Overview

Retinopathy Of Prematurity - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Retinopathy Of Prematurity - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Retinopathy Of Prematurity - Companies Involved in Therapeutics Development

Advanced Imaging Projects Inc

Anida Pharma Inc

D. Western Therapeutics Institute Inc

Everglades Biopharma LLC

F. Hoffmann-La Roche Ltd

Insmed Inc

Novelty Nobility Inc

Orphanix GmbH

Protheragen Inc

Recordati SpA

Regeneron Pharmaceuticals Inc

Signablok Inc

Retinopathy Of Prematurity - Drug Profiles

aflibercept - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drug for Retinopathy of Prematurity - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

mecasermin rinfabate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies to Inhibit SCG3 for Oncology, Ophthalmology and Diabetic Complications - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Inhibit SCG3 for Metabolic Disorders, Oncology and Ophthalmology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Neuroprotectin D1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NN-2901 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Propranolol hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ranibizumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Retinopathy of Prematurity - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides to Inhibit TREM-1 for Oncology, Sepsis, Rheumatoid Arthritis, Retinopathy Of Prematurity and Hemorrhagic Shock - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

vitamin A palmitate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Retinopathy Of Prematurity - Dormant Projects

Retinopathy Of Prematurity - Product Development Milestones

Featured News & Press Releases

Jul 26, 2019: Novartis receives positive CHMP opinion for Lucentis treatment in preterm infants with retinopathy of prematurity (ROP), a disease causing visual impairment and blindness

Mar 11, 2019: Bascom Palmer’s Dr. Wei Li awarded .12 million NEI grant

Sep 22, 2018: Novartis to file for new Lucentis (ranibizumab) indication in retinopathy of prematurity (ROP), a rare disease in premature infants that often leads to blindness

Jun 30, 2016: Shire Announces Top-Line Results for Phase 2 Trial of SHP607 in Extremely Premature Infants

Jan 21, 2009: Insmed And Premacure Announce European Orphan Designation For IPLEX In Retinopathy Of Prematurity In Infants

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Additional Details

Publisher

Global Markets Direct

Publisher Information

Reference

1464120 | GMDHC11483IDB

Number of Pages

67

Report Format

PDF

Related Reports

Title
Date Published
Price From
Link

Published by Global Markets Direct
28-04-2017

$2,000 USD

Published by Global Markets Direct
28-04-2017

$2,000 USD

Published by S&P Consulting
15-03-2017

$3,800 USD

This report is published by Global Markets Direct

Global Markets Direct is a global market intelligence services company providing information research and analysis products and services.

Their highly qualified team of Researchers, Analysts and Solution Consultants use proprietary data sources and various tools and techniques to gather, analyse and represent the latest and the most reliable information essential for businesses to sustain a competitive edge.

Download Free Report Summary PDF

Retinopathy Of Prematurity - Pipeline Review, H2 2019 | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.